Financials in USD. Standardized financial statements.
A compact view of how Biocartis Group N.V. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Revenue? | $57.48M | $48.27M | $43.13M | $37.44M |
| Revenue Growth? | +19.1% | +11.9% | +15.2% | 0.0% |
| Cost of Revenue? | $29.80M | $33.92M | $26.28M | $21.33M |
| Gross Profit? | $27.68M | $14.35M | $16.84M | $16.12M |
| Gross Margin? | +48.2% | +29.7% | +39.1% | +43.0% |
| Operating Expenses? | $74.43M | $76.64M | $63.23M | $71.46M |
| Operating Income? | -$47.05M | -$62.65M | -$46.86M | -$55.60M |
| EBITDA? | -$43.95M | -$52.55M | -$43.23M | -$47.35M |
| Income Before Tax | -$65.62M | -$71.72M | -$63.16M | -$64.17M |
| Income Tax Expense | -$240,000 | -$243,000 | -$228,000 | -$99,000 |
| Net Income? | -$65.38M | -$71.47M | -$62.93M | -$64.07M |
| EPS? | $-1.08 | $-1.24 | $-1.11 | $-1.14 |
| Diluted EPS? | $-1.08 | $-1.24 | $-1.11 | $-1.14 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality